for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ligand Pharmaceuticals Inc.

LGND.O

Latest Trade

104.71USD

Change

-0.83(-0.79%)

Volume

161,171

Today's Range

102.82

 - 

105.64

52 Week Range

84.45

 - 

214.44

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
105.54
Open
104.71
Volume
161,171
3M AVG Volume
9.28
Today's High
105.64
Today's Low
102.82
52 Week High
214.44
52 Week Low
84.45
Shares Out (MIL)
19.01
Market Cap (MIL)
2,006.47
Forward P/E
32.51
Dividend (Yield %)
--

Next Event

Q3 2019 Ligand Pharmaceuticals Inc Earnings Release

Latest Developments

More

Ligand Pharmaceuticals Recently Entered Into An OmniAB Commercial Platform License Agreement With Kira Pharmaceuticals

Ligand Pharma Says On Sept 11, Board Approved Stock Repurchase Program Authorizing, But Not Obligating, Repurchase Of Up To $500 Million Of Stock Over Next 3 Yrs

Ligand Pharmaceuticals Reports Q2 Loss Per Share $0.74

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ligand Pharmaceuticals Inc.

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Industry

Biotechnology & Drugs

Contact Info

3911 Sorrento Valley Blvd Ste 110

+1.858.5507500

https://www.ligand.com/

Executive Leadership

John W. Kozarich

Non-Executive Independent Chairman of the Board

Matthew W. Foehr

President, Chief Operating Officer

John L. Higgins

Chief Executive Officer, Director

Matthew E. Korenberg

Chief Financial Officer, Executive Vice President - Finance

Charles S. Berkman

Senior Vice President, General Counsel, Secretary

Key Stats

1.83 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.3K

2019(E)

0.1K
EPS (USD)

2016

3.330

2017

3.260

2018

7.150

2019(E)

3.246
Price To Earnings (TTM)
3.36
Price To Sales (TTM)
11.55
Price To Book (MRQ)
1.96
Price To Cash Flow (TTM)
2.87
Total Debt To Equity (MRQ)
62.54
LT Debt To Equity (MRQ)
59.94
Return on Investment (TTM)
46.42
Return on Equity (TTM)
37.02

Latest News

Latest News

REFILE-BRIEF-Ligand Pharma - Entered A Worldwide Commercial Platform License Agreement With Genagon Therapeutics AB

* LIGAND PHARMACEUTICALS INC - ON FEB 4 ENTERED INTO A WORLDWIDE COMMERCIAL PLATFORM LICENSE AGREEMENT WITH GENAGON THERAPEUTICS AB

BRIEF-Ligand Prices Offering Of $650 Mln Of Convertible Senior Notes

* LIGAND PRICES OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES

BRIEF-Ligand Pharmaceuticals Announces Proposed Offering Of $650 Mln Of Convertible Senior Notes

* LIGAND ANNOUNCES PROPOSED OFFERING OF $650 MILLION OF CONVERTIBLE SENIOR NOTES

BRIEF-Ligand Pharmaceuticals Entered Commercial Platform License Agreement, With KSQ Therapeutics

* LIGAND PHARMACEUTICALS - ON MAY 8, ENTERED COMMERCIAL PLATFORM LICENSE AGREEMENT, WITH KSQ THERAPEUTICS, INC - SEC FILING

BRIEF-Ligand Reports Q1 Adjusted Earnings Per Share $1.55

* Q1 EARNINGS PER SHARE VIEW $1.15 -- THOMSON REUTERS I/B/E/S

BRIEF-Ligand Pharma Says Co Sent Computershare, As Rights Agent Under Glucagon CVR Agreement

* LIGAND PHARMACEUTICALS SAYS HOLDERS OF GLUCAGON CVRS ENTITLED TO RECEIVE PRO RATA $3.8 MILLION Source text: (https://bit.ly/2JHfcOF) Further company coverage:

BRIEF-Ligand Enters Into Agreement With venBio

* LIGAND ENTERS INTO AGREEMENT WITH VENBIO TO MAKE WORLDWIDE OMNIAB® PLATFORM LICENSE ACCESSIBLE TO PORTFOLIO COMPANIES Source text for Eikon: Further company coverage:

BRIEF-Ligand Pharmaceuticals Says ‍Entered Amendment No. 5 To Sublicense Agreement With Retrophin

* LIGAND PHARMACEUTICALS SAYS ON MARCH 20, CO ENTERED INTO AMENDMENT NO. 5 TO SUBLICENSE AGREEMENT, DATED FEB 16, 2012 WITH RETROPHIN, INC- SEC FILING

BRIEF-Ligand Pharma Says‍ Underreported Potential Aggregate Milestone Payments Related To License Agreement With Roivant Sciences

* LIGAND PHARMACEUTICALS SAYS UNDERREPORTED POTENTIAL AGGREGATE MILESTONE PAYMENTS RELATED TO LICENSE AGREEMENT WITH ROIVANT SCIENCES FOR LGD-6972

BRIEF-Ligand Pharma To Receive Total Potential License & Milestone Payments Of Up To $533.8 Mln, Per Agreement With Roivant

* LIGAND PHARMACEUTICALS - PER TERMS OF LICENSE AGREEMENT WITH ROIVANT, CO TO RECEIVE TOTAL POTENTIAL LICENSE & MILESTONE PAYMENTS OF UP TO $533.8 MILLION

BRIEF-Ligand Pharma Signs License Agreement

* LIGAND PHARMACEUTICALS INC - SIGNED LICENSE AGREEMENT GRANTING ROIVANT SCIENCES EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE LGD-6972 Source text for Eikon: Further company coverage:

BRIEF-Ligand Posts Q4 Adjusted Earnings Per Share $1.31

* LIGAND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Ferring Says Specific Financial Details Of Transaction With Ligand Pharma Are Not Disclosed​

* FERRING ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH LIGAND

BRIEF-Ligand Enters Into Worldwide Omniab Platform License Agreement With Ferring Pharmaceuticals

* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH FERRING PHARMACEUTICALS

BRIEF-Ligand Pharma And Glenmark Pharma Enter Into License Agreement

* LIGAND ENTERS INTO WORLDWIDE OMNIAB® PLATFORM LICENSE AGREEMENT WITH GLENMARK PHARMACEUTICALS

BRIEF-Ligand Earns $6 Million As Omniab Partner Out-Licenses Antibody Projects

* LIGAND EARNS $6 MILLION AS OMNIAB PARTNER OUT-LICENSES ANTIBODY PROJECTS

BRIEF-Ligand Pharmaceuticals - Expects Reduction Of Corporate Tax Rate To Reduce Deferred Tax Asset On Balance Sheet By About $40 Mln

* LIGAND PHARMACEUTICALS - EXPECTS REDUCTION OF CORPORATE TAX RATE TO REDUCE DEFERRED TAX ASSET ON BALANCE SHEET BY ABOUT $40 MILLION AS OF SEPT 30, 2017 Source text: (http://bit.ly/2zy8ap7) Further company coverage:

BRIEF-Ligand Pharma reaffirms 2017 revenue guidance between $134 mln and $136 mln

* Ligand Pharmaceuticals-reaffirmed full-year 2017 revenue guidance of between $134 million and $136 million and adjusted EPS guidance of between $2.95 to $3.00

BRIEF-Ligand Pharmaceuticals says signed license and supply agreement via subsidiary with Meridian Laboratories​

* Ligand Pharmaceuticals Inc - on Nov. 10, 2017, co signed a license agreement and a supply agreement via a subsidiary with Meridian Laboratories Inc

BRIEF-Ligand Q3 adjusted earnings per share $0.69

* Q3 earnings per share view $0.61 -- Thomson Reuters I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up